Black Diamond Therapeutics, a clinical-stage precision oncology company, is set to present groundbreaking research in precision oncology at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place in Boston from October 11-15, 2023.
During the conference, Black Diamond Therapeutics will present three poster presentations covering various aspects of their research. These presentations include initial dose escalation data from the Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of the ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933.
One of the presentations titled Preclinical Efficacy of BDTX-4933 will be given by Elizabeth Buck, Ph.D., who serves as the Chief Scientific Officer at Black Diamond Therapeutics. This presentation will highlight the preclinical data for BDTX-4933, a brain-penetrant RAF inhibitor that targets oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations. The presentation will take place during Poster Session A on Thursday, October 12, from 12:30 pm to 4:00 pm.
BDTX-1535, one of the key programs being developed by Black Diamond Therapeutics, is a brain-penetrant and potent inhibitor of oncogenic mutations in the epidermal growth factor receptor (EGFR) in NSCLC. It has the potential to target approximately 50 different mutations across a diverse group of patients in multiple lines of therapy. BDTX-1535 may also be effective in treating patients with glioblastoma multiforme (GBM) expressing EGFR alterations. Currently, the Phase 1 clinical trial for BDTX-1535 is in dose expansion for NSCLC and dose escalation for GBM.
Black Diamond Therapeutics is a precision oncology medicine company focused on developing therapies that address families of oncogenic mutations in clinically validated targets. By leveraging their deep understanding of cancer genetics and onco-protein structure and function, the company aims to discover and develop innovative therapies. Their MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain-penetrant to address the significant unmet medical needs of patients with genetically defined cancers.
Overall, Black Diamond Therapeutics’ research and development efforts aim to advance precision oncology therapies that target specific mutations and provide new treatment options for patients with genetically defined cancers. By presenting their groundbreaking research at the AACR-NCI-EORTC conference, they hope to contribute to the scientific community’s understanding of precision oncology and its potential in improving patient outcomes.
For more information on Black Diamond Therapeutics and their ongoing research and development programs, please visit their website at www.blackdiamondtherapeutics.com.
